EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro and in vivo study of the inhibition of ubiquinone biosynthesis in Leishmania (Leishmania) amazonensis using the combination of buparvaquone and 4-nitrobenzoate as a strategy for the discovery of new therapeutic targets

Juliana Tonini Mesquita iD, Gabriel Cândido Moura, Tainá Cavalcante, Jenicer Kazumi Umada Yokoyama Yasunaka, Manoel Aparecido Peres, Claudia Blanes Angeli, Noemi Nosomi Taniwaki, Beatriz Simonsen Stolf, Giuseppe Palmisano iD, Alejandro Miguel Katzin iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00824-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Juliana Tonini Mesquita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Naphthoquinones, Antiprotozoal Agents, Ubiquinone, Nitrobenzoates. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmaniasis is a parasitic disease caused by several species of the genus Leishmania, considered one of the most dangerous neglected tropical diseases in the world. Treatment options are limited and toxicity exists, requiring an urgent search for new therapies. Leishmania differs from mammalian cells by having unique mitochondria, which have been considered an important therapeutic target. Ubiquinone is found in the inner membrane of mitochondria and plays a critical role in the electron transport chain, which is essential for cell viability. The combination of buparvaquone and 4-nitrobenzoate seems an interesting option due to their action on these targets. The aim of the present work was to investigate the effects of this combination against Leishmania (Leishmania) amazonensis infections in vitro and in vivo and to elucidate the possible mechanism of action of 4-nitrobenzoate. The results showed that the drug combination tested in promastigotes has an additive or indifferent effect. In the intracellular amastigotes, when buparvaquone was tested with fixed concentrations of 4-nitrobenzoate, concentrations that had no effect alone potentiated the effect of buparvaquone by two to four times. The mechanism of action of 4-nitrobenzoate in promastigote forms suggests a reduction in ubiquinone 6 levels, an alteration in mitochondrial membrane potential, and an increase in reactive oxygen species. In vivo treatment with a topical formulation (buparvaquone 0.1% and 4-nitrobenzoate 0.1%) in infected mice showed a reduction in parasite burden of 57% compared to the control group, suggesting that this combination may represent a promising therapeutic strategy for future treatment of this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaphthoquinonesAntiprotozoal AgentsUbiquinoneNitrobenzoatesLeishmaniaLeishmania mexicanaAnimalsMiceMice, Inbred BALB CFemaleReactive Oxygen SpeciesMitochondriaLeishmaniasisMembrane Potential, MitochondrialDrug Therapy, Combination

Stichwörter der Autor:innen

Leishmania (Leishmania) amazonensiscombination therapyleishmaniasistreatmentubiquinone therapeutic target

Substanzen

NaphthoquinonesAntiprotozoal AgentsUbiquinonebuparvaquoneNitrobenzoatesReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
  • Electron Microscopy Nucleus, Institute Adolfo Lutz, São Paulo, São Paulo, Brazil.

ORCID-Profile: Juliana Tonini Mesquita, Giuseppe Palmisano, Alejandro Miguel Katzin

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Mesquita, J. T., Moura, G. C., Cavalcante, T., Yokoyama Yasunaka, J. K. U., Peres, M. A., Blanes Angeli, C., Taniwaki, N. N., Simonsen Stolf, B., Palmisano, G., & Katzin, A. M. (2025). In vitro and in vivo study of the inhibition of ubiquinone biosynthesis in Leishmania (Leishmania) amazonensis using the combination of buparvaquone and 4-nitrobenzoate as a strategy for the discovery of new therapeutic targets. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00824-25

Vancouver

Mesquita JT, Moura GC, Cavalcante T, Yokoyama Yasunaka JKU, Peres MA, Blanes Angeli C, et al. In vitro and in vivo study of the inhibition of ubiquinone biosynthesis in Leishmania (Leishmania) amazonensis using the combination of buparvaquone and 4-nitrobenzoate as a strategy for the discovery of new therapeutic targets. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00824-25

BibTeX
@article{Mesquita2025,
  author = {Mesquita, Juliana Tonini and Moura, Gabriel Cândido and Cavalcante, Tainá and Yokoyama Yasunaka, Jenicer Kazumi Umada and Peres, Manoel Aparecido and Blanes Angeli, Claudia and Taniwaki, Noemi Nosomi and Simonsen Stolf, Beatriz and Palmisano, Giuseppe and Katzin, Alejandro Miguel},
  title = {In vitro and in vivo study of the inhibition of ubiquinone biosynthesis in Leishmania (Leishmania) amazonensis using the combination of buparvaquone and 4-nitrobenzoate as a strategy for the discovery of new therapeutic targets},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00824-25}
}
Kostenlos starten →